Inhibrx Biosciences旗下INBRX-106在II期头颈鳞癌研究中：缓解率近乎翻倍，无进展生存期中位数达9.6个月

美股速递09-08

Inhibrx Biosciences（INBX）公布了其候选药物INBRX-106在II期头颈鳞状细胞癌（HNSCC）临床研究中的中期数据。结果显示，该药物将缓解率提升近一倍，且无进展生存期（PFS）中位数达到了9.6个月，展现出令人鼓舞的抗肿瘤活性。这些数据预计将为后续的临床试验设计和潜在监管沟通提供关键支撑。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/1179108181?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-09-08 19:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179108181","market":"us","top_or_hot":-1,"title":"Inhibrx Biosciences旗下INBRX-106在II期头颈鳞癌研究中：缓解率近乎翻倍，无进展生存期中位数达9.6个月","media":"美股速递","content":"<p>Inhibrx Biosciences（INBX）公布了其候选药物INBRX-106在II期头颈鳞状细胞癌（HNSCC）临床研究中的中期数据。结果显示，该药物将缓解率提升近一倍，且无进展生存期（PFS）中位数达到了9.6个月，展现出令人鼓舞的抗肿瘤活性。这些数据预计将为后续的临床试验设计和潜在监管沟通提供关键支撑。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inhibrx Biosciences旗下INBRX-106在II期头颈鳞癌研究中：缓解率近乎翻倍，无进展生存期中位数达9.6个月</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInhibrx Biosciences旗下INBRX-106在II期头颈鳞癌研究中：缓解率近乎翻倍，无进展生存期中位数达9.6个月\n</h2>\n\n<h4 class=\"meta\">\n\n2026-09-08 19:31 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Inhibrx Biosciences（INBX）公布了其候选药物INBRX-106在II期头颈鳞状细胞癌（HNSCC）临床研究中的中期数据。结果显示，该药物将缓解率提升近一倍，且无进展生存期（PFS）中位数达到了9.6个月，展现出令人鼓舞的抗肿瘤活性。这些数据预计将为后续的临床试验设计和潜在监管沟通提供关键支撑。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INBX","symbol_name":"Inhibrx Biosciences","start_time":0,"source_url":"","article_id":"1179108181","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179108181","pubTimestamp":1788867080,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Inhibrx Biosciences（INBX）公布了其候选药物INBRX-106在II期头颈鳞状细胞癌（HNSCC）临床研究中的中期数据。结果显示，该药物将缓解率提升近一倍，且无进展生存期（PFS）中位数达到了9.6个月，展现出令人鼓舞的抗肿瘤活性。这些数据预计将为后续的临床试验设计和潜在监管沟通提供关键支撑。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"INBX":"Inhibrx Biosciences","BK4139":"生物科技"},"translate_title":"Inhibrx Biosciences' INBRX-106 in the Phase II head and neck squamous cell carcinoma study: the response rate nearly doubled, and the median progression-free survival reached 9.6 months.","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INBX":1},"content_text":"Inhibrx Biosciences（INBX）公布了其候选药物INBRX-106在II期头颈鳞状细胞癌（HNSCC）临床研究中的中期数据。结果显示，该药物将缓解率提升近一倍，且无进展生存期（PFS）中位数达到了9.6个月，展现出令人鼓舞的抗肿瘤活性。这些数据预计将为后续的临床试验设计和潜在监管沟通提供关键支撑。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1179108181","isCrawlerRequest":true}